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Abstract
The basal-like breast cancer (BLBC) subtype accounts for a disproportionately high percentage of 
overall breast cancer mortality. The current therapeutic options for BLBC need improvement; 
hence, elucidating signaling pathways that drive BLBC growth may identify novel targets for the 
development of effective therapies. Rho GTPases have previously been implicated in promoting 
tumor cell proliferation and metastasis. These proteins are inactivated by Rho-selective GTPase-
activating proteins (RhoGAPs), which have generally been presumed to act as tumor suppressors. 
Surprisingly, RNA-Seq analysis of the Rho GTPase signaling transcriptome revealed high 
expression of several RhoGAP genes in BLBC tumors, raising the possibility that these genes may 
be oncogenic. To evaluate this, we examined the roles of two of these RhoGAPs, ArhGAP11A 
(also known as MP-GAP) and RacGAP1 (also known as MgcRacGAP), in promoting BLBC. Both 
proteins were highly expressed in human BLBC cell lines, and knockdown of either gene resulted 
in significant defects in the proliferation of these cells. Knockdown of ArhGAP11A caused 
CDKN1B/p27-mediated arrest in the G1 phase of the cell cycle, whereas depletion of RacGAP1 
inhibited growth through the combined effects of cytokinesis failure, CDKN1A/p21-mediated 
RB1 inhibition, and the onset of senescence. Random migration was suppressed or enhanced by 
the knockdown of ArhGAP11A or RacGAP1, respectively. Cell spreading and levels of GTP-
bound RhoA were increased upon depletion of either GAP. We have established that, via the 
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suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and 
propose that RhoGAPs can act as oncogenes in cancer.
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 Introduction
Human breast tumors can be classified into one of five major subtypes (luminal A, luminal 
B, HER2-enriched, basal-like, and normal breast-like) based upon global gene expression 
analyses (1-3). The basal-like subgroup is responsible for a disproportionately high 
percentage of overall breast cancer recurrence and death, and accounts for approximately 
80% of the ‘triple-negative’ breast cancers (4,5), for which the current standard of care is 
limited to conventional cytotoxic chemotherapy (6).
Rho family small GTPases (e.g., RhoA, Rac1, and Cdc42) are intracellular signaling 
molecules belonging to the Ras superfamily (7,8). When GTP-bound, these proteins are 
active and capable of signaling to a diverse array of downstream effectors, through which 
they regulate cellular responses such as cell cycle progression, cytokinesis, survival, 
migration, and polarity. Rho GTPases have been strongly implicated in tumorigenesis (9), 
yet, until recently, these proteins were rarely identified as being mutated in cancer. Instead, 
dysregulated activity of Rho GTPases in cancer more commonly arises through their 
aberrant expression and/or activation.
Rho GTPase activity is regulated by Rho-selective guanine nucleotide exchange factors 
(RhoGEFs), GTPase-activating proteins (RhoGAPs), and guanine nucleotide dissociation 
inhibitors (RhoGDIs). In the context of cancer, RhoGEFs, which promote the formation of 
the active GTP-bound state of Rho GTPases by catalyzing the exchange of GDP for GTP 
(10), are thought to drive tumor growth when overexpressed or aberrantly activated. For 
example, we recently showed that the RhoGEF PREX1 is overexpressed in melanoma and 
that PREX1-deficient mice have impaired metastatic tumor growth (11). In contrast, 
RhoGAPs, which stimulate the intrinsic GTPase activity of Rho proteins and return them to 
an inactive, GDP-bound state (12), are generally presumed to inhibit tumorigenesis (13). For 
example, the RhoGAP DLC1 is commonly lost in cancer through promoter methylation, 
genomic deletion, or enhanced protein degradation (14,15). Hence, the prevailing dogma in 
the field is that Rho GTPases and RhoGEFs are oncogenes in cancer, whereas RhoGAPs are 
tumor suppressors.
Recent evidence has begun to challenge this notion, however. Genomic sequencing has 
revealed frequent somatic mutations of RhoA in peripheral T cell lymphomas (PTCLs) 
(16-18) and in diffuse-type gastric carcinomas (19-21). Surprisingly, unlike Rac1, which has 
gain-of-function mutations in melanoma (22), hotspot mutations in RhoA were identified at 
sites consistent with loss-of-function. In PTCL, the predominant mutation was G17V, which 
abolishes GTP-binding and causes RhoA to act as a dominant-negative inhibitor of RhoGEF 
activity (16-18). Diffuse-type gastric cancers exhibited mutations in the effector binding 
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domain of RhoA, most commonly Y42C (19-21), which prevents binding to the Rho effector 
PKN1 (23). In addition to these mutational analyses, another recent study has shown that 
colorectal cancer growth is accelerated in the presence of dominant-negative (T19N) RhoA 
(24). Taken together, and contrary to the existing paradigm, this emerging evidence suggests 
that, in certain cancers, wild type RhoA may act as a tumor suppressor.
In this study, we analyzed RNA-Seq data of human breast tumors to identify Rho GTPases 
or GTPase regulators that are aberrantly expressed in breast cancer. To our surprise, several 
RhoGAP genes exhibited high expression in the basal-like subtype. Focusing on two of 
these genes, ARHGAP11A and RACGAP1, we characterized their role(s) in promoting 
basal-like breast cancer (BLBC). In basal-like cell lines, both GAPs were required for 
proliferation. Suppression of ArhGAP11A (also known as MP-GAP) expression caused cells 
to undergo cell cycle arrest, whereas RacGAP1 (also known as MgcRacGAP)-depleted cells 
failed to grow as a result of the combined effect of cytokinesis failure and the onset of 
senescence. We propose that ArhGAP11A and RacGAP1 act as oncoproteins in BLBC and 
that GAP-mediated inhibition of RhoA activity is a pro-proliferative mechanism, consistent 
with the emerging view of RhoA as a tumor suppressor.
 Materials and Methods
 Cell Culture
Cells were cultured at 37°C in a humidified/5% CO2 atmosphere. SUM149 and SUM159 
cells (Asterand) were maintained in Ham's F-12 medium (Gibco), 10 mM HEPES, 5 μg/ml 
insulin, 1 μg/ml hydrocortisone, and 5% FBS. HMLE cells (provided by Robert Weinberg, 
MIT) were cultured in mammary epithelial cell growth medium (Lonza). BT474, HCC1937, 
HEK293T, MCF10A, MCF7, MDA-MB-231, MDA-MB-468, and T47D cells were 
purchased from American Type Culture Collection (ATCC) and maintained according to 
ATCC instructions. All cell lines were obtained between 2003 and 2015 and passaged for 
fewer than 6 months after receipt/resuscitation from cell banks. For apoptosis experiments, 
SUM149 or HCC1937 cells were treated with 1 μM staurosporine for 4 or 6 h, respectively.
 Vectors and lentivirus preparation
Target short hairpin RNA (shRNA) sequences (in pLKO.1 vectors) were as follows: non-
silencing (NS) control 5’-CAACAAGATGAAGAGCACCAA-3’, ArhGAP11A sh3 5’-
CTGGTGTCAATAGATATGAAA-3’, ArhGAP11A sh5 5’-
CCTTCTATTACACCTCAAGAA-3’, RacGAP1 sh1 5’-
CAGGTGGATGTAGAGATCAAA-3’, and RacGAP1 sh2 5’-
CTAGGACGACAAGGCAACTTT-3’. A cDNA clone containing the ORF of ARHGAP11A 
(Genbank accession NM_014783) was generated by subcloning bp 2204-3794 of exon 12 
onto the 3’ end of IMAGE clone 5502381 (Genbank accession BC063444, Center for 
Cancer Systems Biology), using an engineered XhoI site and partial overlapping primers to 
excise intervening sequences. Full-length RACGAP1 cDNA was from the Center for Cancer 
Systems Biology (IMAGE clone 5583315, Genbank accession BC032754). ArhGAP11A, 
RacGAP1, and KRAS4B(G12V) cDNAs were subcloned into the pCDH-HA lentiviral 
vector (System Biosciences). Lentivirus particles were produced by transfecting HEK293T 
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cells with target vectors and the ViraPower lentiviral packaging system (ThermoFisher 
Scientific). For lentiviral transduction, cells were incubated with virus for 14 h, passaged 48 
h after initial transduction, and then used in experiments after puromycin selection. We have 
previously described the pCMV-Myc-RhoA Q63L, pCMV-Myc-Rac1 Q61L, and pCMV-
Myc-Cdc42 Q61L vectors (25).
 Immunoblot analyses
Antibodies recognizing the following proteins were used: ArhGAP11A (Abcam, ab113261, 
1:1,000), RacGAP1 (Abnova, H00029127-M01, 1:1,000), Rac1 (BD Biosciences, 610650, 
1:500), HA epitope tag (BioLegend, 901513, 1:500), cyclin D1 (Cell Signaling, 2922, 
1:1,000), MAPK1/3 (ERK; Cell Signaling, 9102, 1:1,000), p21 (Cell Signaling, 2947, 
1:1,000), p27 (Cell Signaling, 2552, 1:1,000), PARP1 (Cell Signaling, 9542, 1:3,000), 
phospho-ERK (Cell Signaling, 4370, 1:1,000), phospho-RB1 (Cell Signaling, 9308, 
1:1,000), phospho-RPS6KA1 (RSK; Cell Signaling, 9344, 1:1,000), RB1 (Cell Signaling, 
9309, 1:1,000), RhoA (Cell Signaling, 2117, 1:1,000), actin (EMD Millipore, MAB1501, 
1:10,000), Cdc42 (Santa Cruz, sc-87, 1:200), cyclin E1 (Santa Cruz, sc-247, 1:500), and 
TP53 (Santa Cruz, sc-6243, 1:5,000). Densitometric quantification of blots was performed 
using ImageJ software (NIH).
 Growth assays
For anchorage-dependent clonogenic growth assays, 104 cells/well were grown in 6-well 
plates in the presence or absence of 10 μM of the ROCK1/2 inhibitor Y-27632 (EMD 
Millipore, 688000) for 7 (SUM149) or 10 (HCC1937) days, then stained with 0.2% crystal 
violet in 4% formaldehyde for 20 min. For MTT viability assays, 1,000 cells/well (500 cells/
well for SUM149) were grown in 96 well plates for up to 14 days then stained with 0.3 
mg/ml MTT for 3 h. After solubilizing in dimethyl sulfoxide, A550 was recorded using a 
BioTek Synergy 2 plate reader. MCF10A acinar formation assays were performed as 
previously described (26). For fluorescent microscopy, acini were fixed after 12 days then 
stained with Alexa Fluor 568 phalloidin (ThermoFisher Scientific, A12380, 1:250) and 
Hoechst 33342 (ThermoFisher Scientific, H3570, 1:10,000). Images were taken using a 
Zeiss Axiovert 200M microscope (10× objective), Hamamatsu ORCA-ER camera, and 
Axiovision software. Acinar perimeter and area were determined using ImageJ software 
(NIH).
 Cell cycle analysis
Cells were fixed in 70% ethanol for at least 30 min, stained with 50 μg/ml propidium iodide 
in PBS plus 100 μg/ml RNase for 15 min at 37°C, then analyzed for DNA content using a 
CyAn ADP flow cytometer and Summit software (Beckman Coulter).
 Senescence
Senescence-associated β-galactosidase was detected 7 days post-plating using a staining kit 
(Cell Signaling, 9860), according to the manufacturer's instructions. Images were taken 
using a Nikon Eclipse TS100 microscope (20× objective) and Apple iPhone 6 camera.
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 Spreading assays and fluorescence microscopy
Cells were suspended in Ham's F-12 media, 10 mM HEPES, 5 μg/ml insulin, 1 μg/ml 
hydrocortisone, and 0.5% fatty acid-free bovine serum albumin, rotated end-over-end at 
37°C for 1 h, then plated on 10 μg/ml fibronectin-coated coverslips for 2 h. For fluorescent 
microscopy, cells were fixed and then stained with Alexa Fluor 488 phalloidin 
(ThermoFisher Scientific, A12379, 1:500) and Hoechst 33342 (ThermoFisher Scientific, 
H3570, 1:10,000). Images were taken using a Zeiss Axiovert 200M microscope (63× 
objective), Hamamatsu ORCA-ER camera, and Axiovision software. Cell area was 
determined using ImageJ software (NIH); multinucleated cells were excluded from the 
spreading analysis.
 Random migration assay
Cells (5 × 104/well) were plated on 10 μg/ml fibronectin in 35 mm MatTek dishes and 
imaged at 37°C, 5% CO2 every 10 min for 24 h using an Olympus VivaView system (10× 
objective). Random migration was analyzed using the ImageJ software (NIH) Manual 
Tracking plugin, and the Ibidi Chemotaxis and Migration Tool.
 Rho GTPase pulldowns
GTP-bound RhoA, Rac1, and Cdc42 levels were measured as we have previously described 
(27).
 Results
 ArhGAP11A and RacGAP1 are highly expressed in BLBC
To identify components of Rho GTPase signaling networks that are upregulated in BLBC, 
we analyzed RNA-Seq data, coming from 1,201 human breast tumors as part of The Cancer 
Genome Atlas (TCGA) Project (28), for the expression of the 20 Rho GTPase, 79 RhoGEF, 
64 RhoGAP, and three RhoGDI genes across different breast cancer subtypes. Strikingly, a 
number of genes encoding RhoGAPs were found to be highly expressed in tumors of the 
basal-like subtype relative to normal-like (Fig. 1A) or luminal A (Fig. 1B) tumors, which 
have a better prognosis. This was surprising, given that RhoGAPs have been generally 
presumed to act as tumor suppressors. To explore the possibility that RhoGAP genes may in 
fact play oncogenic roles in BLBC, we chose to focus on two GAP genes that were among 
the most highly upregulated Rho GTPase regulators in the basal-like subtype, ARHGAP11A 
and RACGAP1 (Fig. 1A and B). Similarly to the mRNA levels of these genes in human 
tumors (Fig. 1C), protein expression of ArhGAP11A and RacGAP1 in human breast cancer 
cell lines was generally higher in those of the basal-like subtype than in other subtypes (Fig. 
1D, Supplementary Fig. S2A). The basal-like cell lines SUM149 and HCC1937 both 
exhibited high expression of ArhGAP11A and RacGAP1 (Fig. 1D), and we therefore used 
these cell lines to determine the biological function(s) of these proteins in BLBC.
 ArhGAP11A and RacGAP1 are both required for BLBC cell line proliferation
To assess the contribution of ArhGAP11A and RacGAP1 to BLBC cell growth, we stably 
suppressed their expression in SUM149 and HCC1937 cells using two separate lentivirus-
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delivered shRNA constructs per gene. In both cell lines, steady-state ArhGAP11A protein 
expression was consistently reduced by ~90% and ~60% by the sh3 and sh5 vectors, 
respectively, relative to NS or uninfected (labeled as SUM149 or HCC1937) control cells 
(Fig. 2A and B, Supplementary Fig. S1). For RacGAP1, sh1 and sh2 constructs both caused 
~90% knockdown (Fig. 2A and B, Supplementary Fig. S1).
We then performed a clonogenic growth assay to determine the effect of reduced 
ArhGAP11A or RacGAP1 expression on anchorage-dependent proliferation. SUM149 or 
HCC1937 cells depleted of ArhGAP11A or RacGAP1 formed ~70-95% fewer colonies of 
proliferating cells relative to the NS control (Fig. 2C and D). Near-complete suppression of 
proliferation was also observed for each RhoGAP using an MTT viability assay (Fig. 2E and 
F). The failure of BLBC cell lines to proliferate upon depletion of ArhGAP11A or 
RacGAP1 suggests that these GAPs act to promote cancer cell growth. Therefore, our results 
support the hypothesis that ArhGAP11A and RacGAP1 have oncogenic, rather than tumor 
suppressive, roles in BLBC cells. Depletion of these proteins from HER2-enriched (BT474) 
or luminal B (MCF7 and T47D) human breast cancer cell lines also caused defective 
proliferation (Supplementary Fig. S2), indicating that the importance of ArhGAP11A and 
RacGAP1 to breast cancer growth is not restricted to the BLBC subtype alone.
 RacGAP1-knockdown results in cytokinesis failure
We next sought to delineate the mechanism(s) through which ArhGAP11A and RacGAP1 
suppression impaired BLBC growth. Unlike in the presence of the apoptosis-inducing 
compound staurosporine, depletion of ArhGAP11A or RacGAP1 from SUM149 or 
HCC1937 cells did not result in detectable levels of cleaved PARP1, a marker for cell death 
(Fig. 2G and H). Hence, increased apoptosis was not responsible for the proliferation defects 
that arose upon knockdown of ArhGAP11A or RacGAP1.
RacGAP1 has a well-documented role in regulating cytokinesis (29,30), and ArhGAP11A 
has also recently been implicated in the control of this process (31). We therefore examined 
the effect of GAP-knockdown on the efficiency of BLBC cell division. Fluorescence 
microscopy of Hoechst- and phalloidin-stained cells was used to identify bi- or 
multinucleated cells, which form upon cytokinesis failure. Consistent with the established 
role of RacGAP1 in regulating cytokinesis, ~30-40% of SUM149 cells, and ~45% of 
HCC1937 cells became bi/multinucleated upon RacGAP1-knockdown (Fig. 3A, B, and C). 
Hence, cytokinesis failure is likely to contribute to the inability of RacGAP1-depleted cells 
to proliferate. In contrast, knockdown of ArhGAP11A only resulted in ~7-9% of cells 
becoming bi/multinucleated (Fig. 3A, B, and C). Although this slight defect may partially 
contribute to growth impairment, it is insufficient to account for the substantial growth 
defects observed upon depletion of ArhGAP11A (Fig. 2C, D, E, and F).
 ArhGAP11A-depleted cells undergo p27-mediated cell cycle arrest
To gain further insight into the cause of proliferation failure in ArhGAP11A- and RacGAP1-
depleted cells, we next performed flow cytometry analysis of propidium iodide-stained 
SUM149 cells to identify whether GAP-depletion caused defects in cell cycle progression. 
Relative to NS cells, ArhGAP11A-deficient cells accumulated in the G1 phase of the cell 
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cycle (Fig. 4A). Hence, ArhGAP11A is required for efficient cell cycle progression in BLBC 
cells, indicative of an oncogenic role for this GAP.
To elucidate the molecular mechanisms responsible for causing G1 arrest in ArhGAP11A-
depleted SUM149 cells, we determined the expression levels of proteins that regulate G1 to 
S phase cell cycle transition. Notably, phosphorylation and inactivation of the RB1 tumor 
suppressor protein, which promotes G1 to S progression by releasing the inhibition of E2F 
transcription factors, was dramatically reduced upon suppression of ArhGAP11A expression 
(Fig. 4B). RB1 phosphorylation is dependent on cyclin-dependent kinases (CDKs) in 
complex with cyclins D1 and E, but can be prevented by CDK inhibitors such as CDKN2A/
p16, p21, or p27. After knockdown of ArhGAP11A, strong induction of expression of p27 
was detected in SUM149 cells (Fig. 4B). As neither p21 (Fig. 4B) nor p16 (which is deleted 
in SUM149 cells (32)) were detected under the same conditions, these results indicate that 
p27 is the CDK inhibitor responsible for the hypophosphorylation of RB1 and the associated 
G1 arrest that occurs upon depletion of ArhGAP11A. No substantial changes were observed 
in the expression levels of any of the other cell cycle regulators that we tested (Fig. 4B). We 
suggest that p27-mediated arrest is likely to be the major mechanism through which 
ArhGAP11A-depleted cells fail to proliferate.
 RacGAP1-knockdown causes senescence
In contrast to ArhGAP11A, knockdown of RacGAP1 from SUM149 cells did not alter the 
cell cycle profile relative to control cells (Fig. 4A). Despite this, RacGAP1-depleted cells 
also exhibited low levels of RB1 phosphorylation (Fig. 4B). In these cells, the CDK inhibitor 
p21 was upregulated (Fig. 4B), indicating that different pathways are activated in response to 
the depletion of RacGAP1 as compared to ArhGAP11A. As p21-mediated inhibition of RB1 
phosphorylation is a pathway known to induce senescence (33), we next tested to see 
whether senescence may contribute to the growth defect of RacGAP1-deficient cells. Indeed, 
SUM149 and HCC1937 cells depleted of RacGAP1 were found to have enhanced levels of 
senescence-associated β-galactosidase expression (Fig. 4C, D, and E). In contrast, 
ArhGAP11A-knockdown did not induce senescence (Fig. 4C, D, and E), providing further 
support for the distinct roles that ArhGAP11A and RacGAP1 play in BLBC cells: depletion 
of ArhGAP11A leads to decreased growth via p27-mediated cell cycle arrest, whereas 
RacGAP1-deficient cells fail to proliferate as a result of the combined effects of cytokinesis 
failure, p21-induction, and the onset of senescence.
 ArhGAP11A and RacGAP1 regulate cell spreading and migration
In addition to determining the consequences of depletion of ArhGAP11A and RacGAP1 on 
BLBC proliferation, we also examined their roles in regulating cell spreading and migration, 
two processes known to be reliant on Rho GTPase-dependent cytoskeletal dynamics and 
important for invasive and metastatic cancer growth (34). Suppression of the expression of 
either ArhGAP11A or RacGAP1 caused mononucleated SUM149 cells to spread on 
fibronectin with an approximately 30-50% larger area compared to that of NS control cells 
(Fig. 5A). Enhanced spreading was also observed on uncoated glass coverslips 
(Supplementary Fig. S3). As bi/multinucleated cells typically exhibit greatly increased 
spread areas, these cells were excluded from the spreading analysis. These results indicate 
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that both ArhGAP11A and RacGAP1 are involved of the control of cell spreading, 
suggesting that one function of these GAPs may be to regulate the cytoskeleton via Rho 
GTPase signaling. However, the possibility that the spread morphologies of these cells may 
be secondarily linked to the onset of senescence, particularly in the case of RacGAP1-
depleted cells, cannot be excluded.
The effect of ArhGAP11A and RacGAP1 on random migration was assessed using time-
lapse microscopy of cells plated on fibronectin. Tracking the movement of individual cells 
over a 24 h period determined that SUM149 cells treated with ArhGAP11A sh3 had a 
significantly (~45%) reduced mean velocity compared to that of NS cells (Fig. 5B). This 
migratory defect was not observed upon treatment with the ArhGAP11A sh5 construct, most 
likely reflecting the enhanced efficiency of ArhGAP11A knockdown with sh3 compared to 
sh5 (Supplementary Fig. S1I). Surprisingly, the mean migration velocity of RacGAP1-
depleted cells was 32-58% faster than that of NS cells (Fig. 5B). These results indicate that 
ArhGAP11A promotes, whereas RacGAP1 inhibits, BLBC cell migration in vitro.
 RhoA activity is increased upon depletion of ArhGAP11A or RacGAP1
As proliferation, cytokinesis, cell cycle progression, spreading, and migration – processes 
that we have shown to be affected by ArhGAP11A and/or RacGAP1 in BLBC cells – are 
known to be directly regulated by Rho GTPases, we next set out to determine which specific 
Rho GTPases are controlled by these two GAPs. In SUM149 cells, pulldown experiments 
for active GTPases revealed that RhoA, but not Rac1 or Cdc42, was more active upon 
depletion of ArhGAP11A than in NS-treated cells, by an average of 43-82% (Fig. 6A and 
B). This is consistent with ArhGAP11A having catalytic GAP activity toward RhoA, as has 
been demonstrated using in vitro assays (31,35,36). In contrast, RacGAP1 has previously 
been demonstrated to act as a GAP for Rac1 and Cdc42, but not RhoA in vitro (37). To our 
surprise, Rho GTPase pulldown experiments showed that RhoA activity, but not that of Rac1 
or Cdc42, was elevated in SUM149 cells upon depletion of RacGAP1 (Fig. 6A and B). 
These results suggest that RhoA activity in BLBC cells is usually suppressed by 
ArhGAP11A or RacGAP1. To assess whether increased RhoA activity is responsible for the 
proliferation defect of ArhGAP11A- or RacGAP1-depleted cells, we performed clonogenic 
growth assays in the presence of the ROCK protein kinase-selective inhibitor Y-27632. 
ROCK is a downstream effector of RhoA and its inhibition caused a partial rescue of the 
growth defect of ArhGAP11A- or RacGAP1-depleted cells (Fig. 6C), indicating that 
efficient proliferation is dependent on RhoA signaling being restricted. Furthermore, 
transfection of SUM149 cells with a constitutively active RhoA mutant (Q63L) resulted in 
decreased proliferation (Fig. 6D and E), consistent with observations made with another 
constitutively active RhoA mutant (G14V) in Swiss3T3 fibroblasts (38). For comparison, 
constitutively active Rac1 and Cdc42 mutants (Q61L) had no effect on proliferation 
(Supplementary Fig. S4). These results emphasize that persistently elevated RhoA activity is 
prohibitive to growth.
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 ArhGAP11A or RacGAP1 expression elicits oncogenic phenotypes in untransformed 
cells
To assess the effect of ArhGAP11A and RacGAP1 on transformation, we stably 
overexpressed these proteins in untransformed immortalized human MCF10A breast 
myoepithelial cells (Fig. 7A). In MTT assays, expression of ArhGAP11A resulted in 
enhanced MCF10A proliferation, as did expression of a known oncogene, mutationally-
activated KRAS4B(G12V) (Fig. 7B). These data support the idea that ArhGAP11A can act 
as an oncogene and cancer driver. Interestingly, overexpression of HA-RacGAP1 did not 
cause an increase in proliferation relative to empty vector control (Fig. 7B). It is possible 
that other signaling components must also be altered for RacGAP1 to enhance proliferation.
We next performed MCF10A acinar formation assays to evaluate the effect of RhoGAP 
overexpression on mammary epithelial morphogenesis. The expression of oncogenes in 
MCF10A cells can lead to the formation of disrupted acinar morphology; for example, 
KRAS4B(G12V) expression resulted in the formation of large multi-acinar structures (Fig. 
7C). Acini ectopically overexpressing either ArhGAP11A or RacGAP1 exhibited a 
disrupted, less spherical architecture relative to control acini as early as 8 days after plating 
(Fig. 7C and D). This is consistent with an oncogenic effect for both ArhGAP11A and 
RacGAP1.
 Discussion
Our RNA-Seq analysis of human breast tumors identified high expression of several 
RhoGAP genes in the basal-like subtype, raising the possibility that these negative regulators 
of Rho GTPases can act as oncoproteins rather than tumor suppressors in BLBC. To address 
this, we focused on two RhoGAPs that are highly expressed in BLBC, ArhGAP11A and 
RacGAP1, and established that they are essential for the proliferation of basal-like cell lines. 
The mechanisms through which these GAPs promote growth differ, in that ArhGAP11A is 
required for cell cycle progression, whereas cytokinesis is dependent on RacGAP1. Despite 
the divergent functions of these GAPs, both inhibit RhoA. Hence, our results not only 
suggest that RhoGAPs have an oncogenic role in BLBC, but also support recent 
observations that RhoA may act as a tumor suppressor.
While certain RhoGAPs, most notably DLC1 (14,15), have been characterized and well-
validated as tumor suppressors, our findings indicate that this classification is not applicable 
to all members of the RhoGAP family, as had previously been assumed. Compared to 
RhoGEFs, RhoGAPs are relatively poorly characterized, particularly with regard to their 
role in cancer. However, examples of other RhoGAPs having pro-tumorigenic functions in 
breast cancer do exist, such as ArhGAP35 (39), ArhGAP5 (40,41), and ArhGAP31 (42). 
These studies, coupled to our own, provide accumulating evidence that the role of the 
RhoGAP family in cancer is not as straightforward as might be expected from the classical 
interpretation of Rho GTPases as oncogenes. However, our results appear less paradoxical in 
light of recent studies that have identified RhoA mutations in cancer that are consistent with 
reduced activity of this GTPase (16-21). If reduced RhoA activity is indeed advantageous for 
cancer cell proliferation, then it follows that regulation by GAPs would be a means of 
achieving this. Given the diverse functions of RhoA, it is possible that RhoGAPs such as 
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ArhGAP11A and RacGAP1 permit RhoA activity to be decreased in a very precise 
spatiotemporal fashion, such that RhoA can still perform other roles within the cell. This 
could potentially explain why missense mutations and deletions of RhoA are relatively rare 
in breast cancer (<1.5%) (28).
Our results indicate that ArhGAP11A is required for G1 to S phase cell cycle progression in 
BLBC cells. Indeed, depletion of ArhGAP11A caused G1 arrest associated with increased 
p27 expression. ArhGAP11A has previously been implicated in the control of cytokinesis, 
with 18% of HeLa cells failing this process upon its knockdown (31). In SUM149 and 
HCC1937 BLBC cell lines, we did not observe strong defects in cytokinesis upon depletion 
of ArhGAP11A, however. This discrepancy may reflect heterogeneity between cancer cell 
lines, and suggests that ArhGAP11A may have additional, non-cytokinesis-related functions 
in BLBC. In HCT116 colon cancer cells, ArhGAP11A has been shown to regulate invasion, 
but knockdown of this GAP was not reported to affect cell proliferation (35). Despite this, 
depletion of ArhGAP11A reduced tumor growth in vivo (35), which would appear to agree 
with our finding that cells deficient of this GAP had substantial defects in proliferation. High 
expression of ArhGAP11A has also been reported in colorectal, brain, and lung cancers (35), 
suggesting that its pro-tumorigenic role may not just be limited to breast cancer. 
Furthermore, a truncated paralog of ArhGAP11A called ArhGAP11B (which is also highly 
expressed in BLBC, Fig. 1A and B), has recently been shown to promote neocortex 
expansion (43), raising the intriguing possibility that pro-proliferative functions may be 
conserved between these related proteins.
Elevated RacGAP1 expression has also been reported in a variety of cancers, including 
breast, and its overexpression is frequently correlated to poor patient survival and recurrence 
(44-49). Its biological function in cancer is poorly understood, however. In BLBC, we found 
that RacGAP1-depleted cells failed to proliferate as a result of cytokinesis failure, p21-
induction, and the onset of senescence. The role of RacGAP1 in regulating cytokinesis is 
well-established (29,30) and, in BLBC, high levels of this protein may be required to 
facilitate excessive cell division. The GTPase specificity of RacGAP1 is controversial, with 
one study suggesting that this GAP could be converted from a Rac1- to a RhoA-specific 
GAP upon phosphorylation by aurora kinase B (50). Others have refuted this finding, 
however (37). In BLBC cells, similarly to in squamous cell carcinoma cells (46), knockdown 
of RacGAP1 caused an increase in cellular RhoA activity. It is possible that RhoA activity 
may be indirectly altered by the depletion of RacGAP1, for example as a result of 
mislocalized Ect2 – a RhoA-selective RhoGEF whose localization is otherwise regulated by 
RacGAP1 (30).
Despite depletion of either ArhGAP11A or RacGAP1 leading to increased RhoA activity, 
we observed distinct mechanisms of growth suppression in each case. These differences may 
be caused by GAP catalytic-independent functions, discrete spatiotemporal regulation of 
RhoA signaling, or through additional GAP activity on other Rho GTPase substrates. The 
only known catalytic domain found in ArhGAP11A and RacGAP1 is a RhoGAP domain 
but, through their divergent flanking sequences, they are likely to possess scaffolding 
functions and interact with distinct sets of proteins. RacGAP1 is a component of the 
centralspindlin complex during mitosis and cytokinesis, but its function during interphase is 
Lawson et al. Page 10
Cancer Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
not well established. Similarly, little is known about the subcellular localization of 
ArhGAP11A. In future studies, it would be of interest to characterize the localization of 
ArhGAP11A and RacGAP1 in BLBC cells to identify whether this influences their distinct 
abilities to act as oncogenes. Furthermore, a comprehensive biochemical analysis of their 
GTPase substrates, beyond the three that are conventionally evaluated (RhoA, Rac1, and 
Cdc42), would provide additional insight into their GAP-dependent mechanisms of action.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
ArhGAP11A and RacGAP1 are highly expressed in BLBC. A-B, the expression of Rho 
GEF, GAP, GTPase, and GDI genes in basal-like breast tumors is shown relative to their 
expression in (A) normal or (B) luminal A tumors, as determined from TCGA RNA-Seq 
data. The 24 genes with the highest relative expression in the basal-like subtype are shown. 
C, TCGA RNA-Seq data showing row median centered expression levels of ARHGAP11A 
and RACGAP1 mRNA in human breast tumors of different subtype. D, blot analyses for 
ArhGAP11A and RacGAP1 expression in human breast cancer cell lines of different 
subtypes. Actin expression was determined to verify equivalent loading of total protein.
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Figure 2. 
ArhGAP11A and RacGAP1 are both required for BLBC proliferation. A-B, representative 
western blots showing knockdown of ArhGAP11A (left panels) and RacGAP1 (right panels) 
in (A) SUM149 and (B) HCC1937 cells. C, representative images of crystal violet-stained 
clonogenic growth assays with SUM149 (upper) and HCC1937 (lower) cells, with or 
without knockdown of ArhGAP11A or RacGAP1. D, quantification of mean colony 
formation for SUM149 (upper, n = three independent experiments performed in triplicate 
±SEM) and HCC1937 (lower, n = three independent experiments performed in triplicate 
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±SEM) cells, with or without knockdown of ArhGAP11A or RacGAP1, normalized to NS 
control. Statistical significance was determined by one-sample t test relative to the NS 
control. E-F, MTT assays showing mean proliferation of (E) SUM149 and (F) HCC1937 
cells, with or without knockdown of ArhGAP11A or RacGAP1, each from two independent 
experiments performed in triplicate ±SEM. Statistical significance, relative to the NS 
control, was determined by one-way ANOVA with Dunnett's post-hoc test. G-H, blot 
analyses showing PARP1 cleavage in (G) SUM149 and (H) HCC1937 cells, with or without 
knockdown of ArhGAP11A or RacGAP1, or after treatment with 1 μM staurosporine. Actin 
expression was determined to verify equivalent loading of total protein. Data shown are 
representative of three independent experiments.
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Figure 3. 
RacGAP1-knockdown results in cytokinesis failure. A, representative fluorescent images 
showing actin (green) and Hoechst (blue) staining of SUM149 cells with or without 
knockdown of ArhGAP11A or RacGAP1. Scale bar = 20 μm. Arrowheads in merged images 
indicate binucleated cells. B-C, quantification of the percentage of bi/multinucleated (B) 
SUM149 or (C) HCC1937 cells with or without knockdown of ArhGAP11A or RacGAP1 (n 
= three independent experiments in each case ±SEM, ≥ 108 total cells/condition/
experiment). Statistical significance, relative to the NS control, was determined by one-way 
ANOVA with Dunnett's post-hoc test.
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Figure 4. 
ArhGAP11A-depleted cells undergo p27-mediated cell cycle arrest whereas knockdown of 
RacGAP1 causes senescence. A, shown in the upper panels are representative histograms 
indicating the fluorescence intensity of propidium iodide (PI)-stained NS- or ArhGAP11A 
sh3-treated SUM149 cells, as identified using flow cytometry. The relative boundaries of the 
G1, S, and G2/M phases are indicated. Shown in the lower panel is quantification of the 
mean percentage of SUM149 cells in each phase of the cell cycle, with or without 
knockdown of ArhGAP11A or RacGAP1, from three independent experiments performed in 
triplicate ±SEM. Statistical significance for the G1 category is shown relative to the NS 
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control, and was determined by one-way ANOVA with Dunnett's post-hoc test. B, blot 
analyses for the indicated proteins, from one experiment, representative of three. Actin 
expression was determined to verify equivalent loading of total protein. C, representative 
images of senescence-associated β-galactosidase (β-gal)-stained SUM149 cells (in blue), 
with or without knockdown of ArhGAP11A or RacGAP1. D-E, quantification of the mean 
percentage of β-gal-stained (D) SUM149 or (E) HCC1937 cells, with or without knockdown 
of ArhGAP11A or RacGAP1 (n = three independent experiments performed in triplicate in 
each case ±SEM, > 400 total cells/condition/experiment). Statistical significance, relative to 
the NS control, was determined by one-way ANOVA with Dunnett's post-hoc test.
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Figure 5. 
ArhGAP11A and RacGAP1 regulate cell spreading and migration. A, shown in the upper 
panel are representative fluorescent images of actin (green) and Hoechst (blue) staining of 
SUM149 cells, with or without knockdown of ArhGAP11A or RacGAP1, after 2 h on 10 
μg/ml fibronectin-coated coverslips. Scale bar = 20 μm. Shown in the lower panel is 
quantification of mean cell area (n = three independent experiments ±SEM, ≥85 cells/
condition/experiment) after spreading on fibronectin, normalized to NS control. Statistical 
significance was determined by one-sample t test relative to the NS control. Multinucleated 
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cells were excluded from the analysis. B, mean random migration velocity of SUM149 cells, 
with or without knockdown of ArhGAP11A or RacGAP1, on fibronectin-coated coverslips, 
as measured from 24 h time-lapse movies. Data shown were pooled from three independent 
experiments, ≥110 total cell tracks/condition ±SEM. Statistical significance, relative to the 
NS control, was determined by one-way ANOVA with Dunnett's post-hoc test.
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Figure 6. 
RhoA activity is increased upon depletion of ArhGAP11A or RacGAP1. A, blot analyses for 
GTP-bound RhoA, Rac1, and Cdc42 levels in SUM149 cells, with or without knockdown of 
ArhGAP11A or RacGAP1, following Rho GTPase pulldown experiments. Total protein 
levels were detected from whole cell lysate (*non-specific band from previous blot). Actin 
expression was determined to verify equivalent loading of total protein. B, densitometric 
quantification of the mean ratio of GTP-bound to total RhoA, Rac1, or Cdc42 (±SEM), from 
seven, eight, or four independent pulldown experiments, respectively. Data were normalized 
to the NS control in each case. Statistical significance was determined by one-sample t test 
relative to the NS control. C, quantification of mean SUM149 colony formation, with or 
without knockdown of ArhGAP11A or RacGAP1, and after treatment with or without 10 
μM Y-27632 (n = four independent experiments performed in triplicate ±SEM, normalized 
to untreated SUM149 cells). Statistical significance between untreated and Y-27632-treated 
samples was determined by two-tailed t test. D, blot analyses for RhoA showing endogenous 
RhoA and overexpression of Myc-RhoA Q63L in SUM149 cells. Actin expression was 
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determined to verify equivalent loading of total protein. E, MTT assay showing SUM149 
cell proliferation in the presence or absence of Myc-RhoA Q63L (n = two independent 
experiments performed in triplicate ±SEM).
Lawson et al. Page 23
Cancer Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. 
ArhGAP11A or RacGAP1 expression elicits oncogenic phenotypes in untransformed cells. 
A, blot analyses for HA-epitope tag (left panels), ArhGAP11A (upper right panels), and 
RacGAP1 (lower right panels) showing overexpression of HA-ArhGAP11A, HA-RacGAP1, 
and HAKRAS4B(G12V) in MCF10A cells. Actin expression was determined to verify 
equivalent loading of total protein. B, MTT assay to monitor MCF10A proliferation in 
empty vector control cells or cells expressing HA-ArhGAP11A, HA-RacGAP1, or HA-
KRAS4B(G12V) (n = three independent experiments performed in triplicate ±SEM). C, 
representative images of actin (green) and Hoechst (blue) stained MCF10A acini expressing 
empty vector control, HA-ArhGAP11A, HA-RacGAP1, or HA-KRAS4B(G12V), after 12 
days growth on Matrigel. Scale bar = 50 μm. D, quantification of relative acini perimeter/
area over time for MCF10A cells expressing empty vector, HA-ArhGAP11A, or RacGAP1. 
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Data shown were pooled from two independent experiments performed in duplicate, ≥161 
total acini/day/condition ±SEM. Statistical significance, relative to the empty vector control, 
was determined by one-way ANOVA with Dunnett's post-hoc test.
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